RE:RE:RE:RE:RE:For anybody interested in the CYDY storyI agree CYDY is a very bad example, but the Sutro comparison shows that Thera, without results on humans in oncology, is fairly valued if you remove the cash both companies have and take into account Thera's 50 M$ debt from the convertible notes.
Wino115 wrote: I know all of us understand what we're talking about here, but it may not serve us to post references to CY on this board in case someone who doesn't know a thing about THTX may find this and make the glaringly wrong conclusion that THTX stock chart looks like it does because of suspicion around it, like "that which will go unnamed". It's such a bad comparison in many ways. Plenty of other highly valued, larger cap biotechs to start comparing THTX to --SeaGen, Sutro, Bicycle, etc...
jfm1330 wrote: It would be fitting to see CYDY back to where it belongs because it is an empty fraudulent shell, and to finally see Thera rise with clear good clinical results out of solid science and steady development work. I really hope it will happen, first for my personal interest, but also as a good lesson about investment. Like a Hollywood movie where the good one wins at the end.